SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): September 10, 2012
CHELSEA THERAPEUTICS INTERNATIONAL, LTD.
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of incorporation)||(Commission File
|(IRS Employer ID Number)|
|3530 Toringdon Way, Suite 200, Charlotte, North Carolina 28277|
|(Address of principal executive offices)||(Zip Code)|
|Registrant’s telephone number, including area code||(704) 341-1516|
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|¨||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|¨||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|¨||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|¨||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Item 8.01. Other Events.
Attached hereto as Exhibit 99.1 is a PowerPoint presentation that Chelsea Therapeutics International, Ltd. will present at the 14th Annual Rodman & Renshaw Global Healthcare Investment Conference on September 10, 2012, and which is incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
|99.1||PowerPoint presentation of September 10, 2012.|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|CHELSEA THERAPEUTICS INTERNATIONAL, LTD.|
|Date: September 10, 2012||/s/ J. Nick Riehle|
|J. Nick Riehle, Chief Financial Officer|